Louis Matis - Net Worth and Insider Trading

Louis Matis Net Worth

The estimated net worth of Louis Matis is at least $2,015 dollars as of 2024-11-13. Louis Matis is the SVP, Chief Development Officer of Pieris Pharmaceuticals Inc and owns about 125 shares of Pieris Pharmaceuticals Inc (PIRS) stock worth over $2,015. Details can be seen in Louis Matis's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Louis Matis has not made any transactions after 2016-06-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Louis Matis

To

Louis Matis Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Louis Matis owns 1 companies in total, including Pieris Pharmaceuticals Inc (PIRS) .

Click here to see the complete history of Louis Matis’s form 4 insider trades.

Insider Ownership Summary of Louis Matis

Ticker Comapny Transaction Date Type of Owner
PIRS Pieris Pharmaceuticals Inc 2016-06-14 SVP & Chief Development Officer

Louis Matis Latest Holdings Summary

Louis Matis currently owns a total of 1 stock. Louis Matis owns 125 shares of Pieris Pharmaceuticals Inc (PIRS) as of June 14, 2016, with a value of $2,015.

Latest Holdings of Louis Matis

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PIRS Pieris Pharmaceuticals Inc 2016-06-14 125 16.12 2,015

Holding Weightings of Louis Matis


Louis Matis Form 4 Trading Tracker

According to the SEC Form 4 filings, Louis Matis has made a total of 0 transactions in Pieris Pharmaceuticals Inc (PIRS) over the past 5 years. The most-recent trade in Pieris Pharmaceuticals Inc is the acquisition of 125 shares on June 14, 2016, which cost Louis Matis around $17,000.

Insider Trading History of Louis Matis

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Louis Matis Trading Performance

GuruFocus tracks the stock performance after each of Louis Matis's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Louis Matis is -4.27%. GuruFocus also compares Louis Matis's trading performance to market benchmark return within the same time period. The performance of stocks bought by Louis Matis within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Louis Matis's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Louis Matis

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 5.49 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 1.23 LIMIT LIMIT LIMIT LIMIT LIMIT

Louis Matis Ownership Network

Ownership Network List of Louis Matis

No Data

Ownership Network Relation of Louis Matis

Insider Network Chart

Louis Matis Owned Company Details

What does Pieris Pharmaceuticals Inc do?

Who are the key executives at Pieris Pharmaceuticals Inc?

Louis Matis is the SVP & Chief Development Officer of Pieris Pharmaceuticals Inc. Other key executives at Pieris Pharmaceuticals Inc include 10 percent owner Bvf Gp Holdings Llc , other: See Explanation of Responses Bvf Ii Gp Llc , and 10 percent owner Bvf I Gp Llc .

Pieris Pharmaceuticals Inc (PIRS) Insider Trades Summary

Over the past 18 months, Louis Matis made no insider transaction in Pieris Pharmaceuticals Inc (PIRS). Other recent insider transactions involving Pieris Pharmaceuticals Inc (PIRS) include a net purchase of 10,000 shares made by Christopher P Kiritsy , and a net purchase of 6,000 shares made by .

In summary, during the past 3 months, insiders sold 0 shares of Pieris Pharmaceuticals Inc (PIRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pieris Pharmaceuticals Inc (PIRS) were sold and 6,125 shares were bought by its insiders, resulting in a net purchase of 6,125 shares.

Pieris Pharmaceuticals Inc (PIRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Pieris Pharmaceuticals Inc Insider Transactions

No Available Data

Louis Matis Mailing Address

Above is the net worth, insider trading, and ownership report for Louis Matis. You might contact Louis Matis via mailing address: Lise-meitner-strasse 30, C/o Pieris Pharmaceuticals, Inc., Freising-weihenstephan 2m 85354.